Der sås dog ingen forskel fra placebo i forekomsten af forstyrrelser i immunsystemet inden for 48 timer efter administration af Soliris i de PNH- undersøgelser og andre undersøgelser, hvor Soliris blev anvendt.
As with all therapeutic proteins, administration of Soliris may result in infusion reactions or immunogenicity that could cause allergic or hypersensitivity reactions (including anaphylaxis), though immune system disorders within 48 hours of Soliris administration did not differ from placebo treatment in PNH and non-PNH studies conducted with Soliris.